Nuria Chic

Research group

Translational genomics and targeted therapies in solid tumours Pre-doctoral researcher (R1)

chic@clinic.cat 0000-0001-9736-6276

Featured publications

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer

Authors:
Chic, N; Prat, A; Di Cosimo, S; Saura, C; Luen, SJ;

(...)

Hilbers, F; Wang, YB; de Azambuja, E; Láng, I; Huober, J.

Reference: Journal Of The National Cancer Institute 2022.
Gene expression profiles of breast cancer metastasis according to organ site

Authors:
Braso-Maristany, Fara; Pare, Laia; Chic, Nuria; Martinez-Saez, Olga; Pascual, Tomas;

(...)

Adamo, Barbara; Moreno, Reinaldo; Vidal, Maria; Munoz, Montserrat; Prat, Aleix.

Reference: Molecular Oncology 2022.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Authors:
Chic, Nuria; Schettini, Francesco; Braso-Maristany, Fara; Sanfeliu, Esther; Adamo, Barbara;

(...)

Munoz, Montserrat; Perou, Charles M; Pascual, Tomas; Bellet, Meritxell; Prat, Aleix.

Reference: Ebiomedicine 2021.
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Authors:
Prat, A; Chic, N; Martínez-Sáez, O; Brasó-Maristany, F; Paré, L;

(...)

Solovieff, N; Lteif, A; Babbar, N; Su, F; Taran, T.

Reference: Journal Of Clinical Oncology 2021.
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

Authors:
Buus, R; Schuster, EF; Xiao, H; Dowsett, M; Haynes, BP;

(...)

Cuzick, J; Paré, L; Seguí, E; Chic, N; Prat, A.

Reference: Npj Breast Cancer 2021.
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Authors:
Martinez-Saez, Olga; Pascual, Tomas; Braso-Maristany, Fara; Chic, Nuria; Gonzalez-Farre, Blanca;

(...)

Salvador, Fernando; Ciruelos, Eva M; Faull, Iris; Odegaard, Justin I; Prat, Aleix.

Reference: Npj Breast Cancer 2021.
Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial

Authors:
Chic, Nuria; Luen, Stephen; Nuciforo, Paolo; Salgado, Roberto; Fumagalli, Debora;

(...)

Di Cosimo, Serena; Saura, Cristina; Huober, Jens; Prat, Aleix; Loi, Sherene;.

Reference: Cancer Research 2021.
PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype

Authors:
Guarneri, Valentina; Dieci, Maria Vittoria; Bisagni, Giancarlo; Brandes, Alba A; Frassoldati, Antonio;

(...)

Pare, Laia; Chic, Nuria; D'Amico, Roberto; Prat, Aleix; Conte, Pierfranco.

Reference: Clinical Cancer Research 2020.
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

Authors:
Prat, Aleix; Guarneri, Valentina; Pare, Laia; Griguolo, Gaia; Pascual, Tomos;

(...)

Piacentini, Federico; D'Amico, Roberto; Tagtiapco, Enrico; Parker, Joel S; Conte, Pierfranco.

Reference: Lancet Oncology 2020.
Frequency and spectrum of PIK3CA somatic mutations in breast cancer

Authors:
Martinez-Saez, Olga; Chic, Nuria; Pascual, Tomas; Adamo, Barbara; Vidal, Maria;

(...)

Galvan, Patricia; Rodriguez, Ana Belen; Martinez, Antonio; Munoz, Montserrat; Prat, Aleix.

Reference: Breast Cancer Research 2020.

Featured Projects

Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama

Duration: 01/02/2020
Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Duration: 02/12/2019

Nuria Chic

Research group

Featured publications

Celtil score and long-term survival outcome in early stage HER2-positive (HER2+) breast cancer treated with anti-HER2-based chemotherapy: A correlative analysis of neoALTTO trial

Featured Projects

Desarrollo de un test basado en DNA tumoral circulante (ctDNA) para identificar los subtipos moleculares intrínsecos de cáncer de mama

Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Subscribe to the Newsletter of Clínic